313 related articles for article (PubMed ID: 16315051)
41. [S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025) : Compendium].
Knoll T; Bach T; Humke U; Neisius A; Stein R; Schönthaler M; Wendt-Nordahl G
Urologe A; 2016 Jul; 55(7):904-22. PubMed ID: 27325405
[TBL] [Abstract][Full Text] [Related]
42. Urinary metabolic evaluations in solitary and recurrent stone forming children.
DeFoor W; Minevich E; Jackson E; Reddy P; Clark C; Sheldon C; Asplin J
J Urol; 2008 Jun; 179(6):2369-72. PubMed ID: 18433777
[TBL] [Abstract][Full Text] [Related]
43. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: pediatric basic and advanced life support.
International Liaison Committee on Resuscitation
Pediatrics; 2006 May; 117(5):e955-77. PubMed ID: 16618790
[TBL] [Abstract][Full Text] [Related]
44. [Recurrence prevention of urolithiasis with respect to economic aspects].
Siener R; Laube N; Strohmaier WL
Urologe A; 2011 Oct; 50(10):1276, 1278-82. PubMed ID: 21976120
[TBL] [Abstract][Full Text] [Related]
45. 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy.
Osman MM; Alfano Y; Kamp S; Haecker A; Alken P; Michel MS; Knoll T
Eur Urol; 2005 Jun; 47(6):860-4. PubMed ID: 15925084
[TBL] [Abstract][Full Text] [Related]
46. [The methodology of remote monitoring of patients with urinary stone disease: development and primary approbation].
Lebedev GS; Shaderkin IA; Gazimiev MA; Rudenko VI; I DV; Alfimov AE; Vladzimirsky AV; Gazimiev AM
Urologiia; 2021 Nov; (5):26-34. PubMed ID: 34743428
[TBL] [Abstract][Full Text] [Related]
47. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
[TBL] [Abstract][Full Text] [Related]
48. Medical management of kidney stones: AUA guideline.
Pearle MS; Goldfarb DS; Assimos DG; Curhan G; Denu-Ciocca CJ; Matlaga BR; Monga M; Penniston KL; Preminger GM; Turk TM; White JR;
J Urol; 2014 Aug; 192(2):316-24. PubMed ID: 24857648
[TBL] [Abstract][Full Text] [Related]
49. [The role of dynamic observation in the prevention of recurrences of stone formation].
Dzeranov NK; Darenkov AF; Konstantinova OV; Beshliev DA; Borisik VI; Golovanov SA; Drozhzheva VV
Urol Nefrol (Mosk); 1998; (2):12-4. PubMed ID: 9577694
[TBL] [Abstract][Full Text] [Related]
50. [Urolithiasis in pediatrics: analysis of 34 patients].
Wagner U; Balzar E; Ponhold W; Khoss A; Latal D; Zwiauer K
Z Urol Nephrol; 1987 Sep; 80(9):505-11. PubMed ID: 3687252
[TBL] [Abstract][Full Text] [Related]
51. [What foods should stone formers avoid?].
Amasaki N; Kurita T
Hinyokika Kiyo; 2004 Aug; 50(8):573-5. PubMed ID: 15471079
[TBL] [Abstract][Full Text] [Related]
52. Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?
Tiselius HG
Urolithiasis; 2016 Feb; 44(1):91-100. PubMed ID: 26614110
[TBL] [Abstract][Full Text] [Related]
53. International Alliance of Urolithiasis (IAU) guidelines on the metabolic evaluation and medical management of urolithiasis.
Zeng G; Zhu W; Robertson WG; Penniston KL; Smith D; Pozdzik A; Tefik T; Prezioso D; Pearle MS; Chew BH; Veser J; Fiori C; Deng Y; Straub M; Türk C; Semins MJ; Wang K; Marangella M; Jia Z; Zhang L; Ye Z; Tiselius HG; Sarica K
Urolithiasis; 2022 Dec; 51(1):4. PubMed ID: 36454329
[TBL] [Abstract][Full Text] [Related]
54. [Guidelines Clearing House Statement "Hypertension". Summary and recommendations for a rational hypertension guideline in Germany].
Donner-Banzhoff N; Echterhoff HH; Hense HW; Kunz R; Sawicki P; Thürmann P; Jonitz G; Ollenschläger G
Z Arztl Fortbild Qualitatssich; 2000 Jun; 94(5):341-9. PubMed ID: 10939145
[TBL] [Abstract][Full Text] [Related]
55. Metaphylaxis, diet and lifestyle in stone disease.
Kok DJ
Arab J Urol; 2012 Sep; 10(3):240-9. PubMed ID: 26558032
[TBL] [Abstract][Full Text] [Related]
56. [Clinical significance of urinary calculi analysis].
Schmucki O
Helv Chir Acta; 1981 Aug; 48(3-4):477-83. PubMed ID: 7287487
[TBL] [Abstract][Full Text] [Related]
57. Renal phosphate control as a reliable predictive factor of stone recurrence.
Kim YJ; Kim TH; Yun SJ; Kim ME; Kim WJ; Lee SC
J Urol; 2009 Jun; 181(6):2566-72; discussion 2572. PubMed ID: 19375105
[TBL] [Abstract][Full Text] [Related]
58. Improving the compliance of the recurrent stone-former.
Fritsche HM; Dötzer K
Arab J Urol; 2012 Sep; 10(3):342-6. PubMed ID: 26558047
[TBL] [Abstract][Full Text] [Related]
59. Metaphylaxis of nephrolithiasis.
Jacobellis U
Urol Int; 2007; 79 Suppl 1():51-5. PubMed ID: 17726353
[TBL] [Abstract][Full Text] [Related]
60. [The most important factor for active urinary stone formation in patients with urolithiasis].
Simić-Ogrizović S; Dopsaj V; Jovicić S; Milenković D; Jovanović D; Nesić V
Med Pregl; 2007; 60 Suppl 2():117-20. PubMed ID: 18928175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
